By otakuyassine3@gmail.com 
Crossmark Global Holdings Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 2.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 76,607 shares of the medical research company’s stock after buying an additional 1,966 shares during the period. Crossmark Global Holdings Inc.’s holdings in Amgen were worth $19,967,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. XTX Topco Ltd purchased a new stake in shares of Amgen in the second quarter worth about $661,000. Pacer Advisors Inc. lifted its position in shares of Amgen by 8.9% during the second quarter. Pacer Advisors Inc. now owns 74,039 shares of the medical research company’s stock worth $23,133,000 after purchasing an additional 6,048 shares in the last quarter. Certified Advisory Corp grew its holdings in Amgen by 16.0% during the 2nd quarter. Certified Advisory Corp now owns 1,460 shares of the medical research company’s stock valued at $456,000 after purchasing an additional 201 shares in the last quarter. Steel Grove Capital Advisors LLC boosted its position in Amgen by 5.8% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 1,357 shares of the medical research company’s stock valued at $424,000 after buying an additional 74 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its position in shares of Amgen by 74.2% during the second quarter. Public Sector Pension Investment Board now owns 20,647 shares of the medical research company’s stock worth $6,451,000 after acquiring an additional 8,795 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the stock. Bank of America reaffirmed an “underperform” rating and issued a $256.00 price target on shares of Amgen in a report on Tuesday, December 10th. Jefferies Financial Group restated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Wolfe Research initiated coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, William Blair reiterated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $314.91.
View Our Latest Report on AMGN
Amgen Trading Up 1.0 %
AMGN stock opened at $272.11 on Tuesday. The business has a fifty day moving average of $273.95 and a 200-day moving average of $307.18. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a market cap of $146.27 billion, a P/E ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.
Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.96 EPS. As a group, equities research analysts expect that Amgen Inc. will post 19.57 EPS for the current year.
Amgen Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 121.90%.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Articles
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.